Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCellular is still pretty much an unknown.
Continue reading Inside Wall Street: Is ImmunoCellular Another Rising Star in Biotech?
Inside Wall Street: Is ImmunoCellular Another Rising Star in Biotech? originally appeared on DailyFinance on Mon, 22 Nov 2010 07:30:00.
Filed Under: Company News, Columns, Investing, Health Care, Pfizer, Stock Picks, GlaxoSmithKline, Streetwise